source
- AbbVie and Genmab's Epkinly succeeds in late-stage first-line DLBCL trial, challenging Roche's PolivyAbbVie and Genmab announced that their T‑cell engager Epkinly met its primary endpoints in a late‑stage study evaluating first‑line treatment for diffuse large B‑cell lymphoma (DLBCL). The trial de…
- Forbion raises €2.3 billion with Lilly backing, launches largest Dutch VC fund to back ~30 life-science firmsForbion, a Netherlands-based life-science investor, announced it has closed two new funds totaling €2.3 billion ($2.6 billion), the largest capital raise in Dutch venture-capital history. The fund…